MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 |
| [13-February-2026] |
Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended Further CAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity and related metabolic disorders. This currently includes 39 granted and pending patents in the U.S. and internationally, providing protection into 2041, unless extended further.
MetaVia's patent portfolio, exclusively licensed from Dong-A ST Co., Ltd., provides broad protection covering the novel peptide structure of DA-1726 as well as its design as a long-acting dual-incretin therapy. Together, these protect both the core molecule and its therapeutic use in obesity, metabolic disease, and associated cardiometabolic conditions, strengthening the company's long-term development and commercialization position in one of the fastest-growing areas of medicine. "Building a strong and durable patent foundation is essential as we advance DA-1726 as a potential best-in-class therapy for obesity and metabolic disease," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Our intellectual property estate protects the unique design of this dual GLP-1/glucagon agonist and supports the long-term value of the program. As importantly, our recent clinical data reinforce the promise of DA-1726. At the 48 mg dose, we saw meaningful weight loss of about 9%, significant reductions in waist size, improvements in blood sugar levels, and early signs of direct liver benefit, all with a favorable safety profile." Mr. Kim continued, "Looking ahead, our planned 16-week titration studies to 48 mg and 64 mg reflect our confidence in the therapy's tolerability and its potential to offer an advantage over the slower dose-escalation schedules required by current GLP-1 treatments. With results expected in the fourth quarter of 2026, we believe we are well positioned to unlock additional value as we advance DA-1726 into later-stage development." About DA-1726 About MetaVia For more information, please visit www.metaviatx.com. Forward Looking Statements Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts: MetaVia Rx Communications Group
SOURCE MetaVia Inc. | ||
Company Codes: NASDAQ-NMS:MTVA |
View original content to download multimedia:
